News Gilead files first hepatitis delta therapy with FDA Gilead Sciences has submitted its marketing application for bulevirtide, its antiviral therapy for rare hepatitis delta virus (HDV) infections, to the FDA.
News Better slashes staff in another digital health retreat Company will cut its headcount by 35%, as it waits for an FDA decision on its diabetes DTx.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK